TScan Therapeutics Announces $30 Million Registered Direct OfferingOn December 26, 2024, TScan Therapeutics, Inc. (NASDAQ: TCRX) entered into a securities purchase agreement with Lynx1 Capital Management LP, an existing shareholder, and an investment
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read TScan Therapeutics’s 8K filing here. TScan Therapeutics Company Profile (Get Free Report) TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients […]
More Stories
Iran Offered Better Deal ‘10 Minutes’ After US Canceled Pakistan Meeting, Trump Says
By Jacki Thrapp The Iranian regime offered the United States a “much better” peace deal within 10 minutes of President...
Iran Delegation Leaves Pakistan Without US Talks as Trump Cancels Envoy Visit
By Tom Ozimek Iranian Foreign Minister Abbas Araghchi left Pakistan for Oman on Saturday without meeting U.S. negotiators. Araghchi met...
SBA Refers 562,000 Suspected Fraudulent Loans Worth $22.2 Billion to Treasury
By Naveen Athrappully The Small Business Administration (SBA) has referred 562,000 loans suspected to be fraudulent to the Treasury Department...
US Exports of Crude and Petroleum Products Hit Record Highs
By Jacki Thrapp America’s energy exports have hit record highs as the world navigates the uncertainty surrounding oil and gas...
New Listings Tick Up 3 Percent as Mortgage Rates Continue to Slide
By Rob Sabo New home listings are on the rise across the United States, potentially spurred by hopes of falling...
US, EU Sign Preliminary Partnership Deal on Critical Minerals
By Owen Evans The United States and the European Union signed a memorandum of understanding on April 24 for a...